gvtcx

PHE - Corporate - Acute Drug Harms Surveillance and Early Warning System in UK

Public Health England Published 14 Apr 2023 Contracts Finder

key details

Statuscomplete
Category (CPV) 75122000
Deadline12 Jul 2021
Contract start1 Sept 2021
Contract end31 Aug 2022
Procedureopen
SME suitableYes
OCIDocds-b5fd17-a06853df-1e06-41d8-bb04-11f6e6f7ec58

Award

SupplierValueDateStatus
Newcastle University £99,676 5 Sept 2021 active

description

Public Health England (PHE) is seeking to commission an external partner with an existing system and / or capability to deliver an opioid and new psychoactive substances (NPS) clinical harms surveillance programme. The programme will:

rapidly detect any incident involving synthetic opioids in the heroin or cocaine markets;
monitor the emergence of a synthetic opioid market as seen in North America;
identify health harms associated with toxicity from emerging/new NPS, such as synthetic cannabinoids.

The programme will involve laboratory testing of biological samples from A&E patients around the UK who have been treated for adverse reactions to illicit drugs. Participating A&E departments will take and submit biological samples from suitable patients. These samples will be toxicologically analysed and assessed, alongside other intelligence sources. Any emerging trends and signals of interest will be reported to PHE to ensure that drug health harms are identified and acted upon promptly.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
14 Apr 2023 Award (award) · da6843ef-6617-4b59-811c-2e0f11e3b8c9-635316

more from Public Health England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.